Trial intelligence / Profile preview

Ancillary biomarker study of nivolumab in relapsed/refractory peripheral T‑cell lymphoma (W-JHS NHL02-A)

jRCT1071210120Active, not recruiting

Sponsor: Kyushu University Hospital
Start: Apr 2019
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Open-label, single-arm trial of nivolumab in peripheral T-cell lymphoma (PTCL) and extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Kyushu University Hospital. Primary endpoints: Gene and protein expression analysis, Gene mutation analysis and 4 more. Started Apr 2019; status: active, not recruiting.

Drugs

nivolumab

Conditions

peripheral T-cell lymphoma (PTCL)extranodal natural killer/T-cell lymphoma (ENKTL)

Beyond the preview

Go deeper on jRCT1071210120.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT1071210120.